Overview Financials News + Filings Key Docs Charts Ownership Insiders |
Gigamon Inc. (GIMO)
|
Add to portfolio |
|
|
Price: |
$38.50
| | Metrics |
OS: |
37.3
|
M
| |
|
% ROE
|
Market cap: |
$1.44
|
B
| |
-1
|
% ROIC
|
Net cash:
|
$265
|
M
| |
$7.09
|
per share
|
EV:
|
$1.17
|
B
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
($692.0)
|
k
| |
|
|
EBIT
|
($6.9)
|
M
| |
|
|
EPS |
($0.03)
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-16 | Dec-26-15 | Dec-27-14 | Dec-28-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
Revenues | 310.9 | 222.0 | 157.1 | 140.3 | 96.7 | 68.1 | 46.5 | 31.4 |
Revenue growth | 40.0% | 41.3% | 12.0% | 45.1% | 42.0% | 46.5% | 48.1% | |
Cost of goods sold | 54.8 | 45.8 | 37.4 | 30.8 | 20.3 | 14.4 | 8.4 | 5.5 |
Gross profit | 256.1 | 176.2 | 119.7 | 109.5 | 76.4 | 53.7 | 38.1 | 25.9 |
Gross margin | 82.4% | 79.4% | 76.2% | 78.0% | 79.0% | 78.8% | 82.0% | 82.5% |
Selling, general and administrative | | | | | | | | |
Sales and marketing | 122.7 | 87.5 | 76.1 | 72.0 | 39.4 | 19.4 | 12.5 | 5.2 |
Research and development | 68.1 | 49.6 | 42.8 | 42.1 | 17.7 | 12.5 | 12.3 | 5.0 |
General and administrative | 34.9 | 27.5 | 20.7 | 25.6 | 11.7 | 4.8 | 6.6 | 2.5 |
EBIT | 30.4 | 11.6 | -19.9 | -30.2 | 7.7 | 17.0 | 6.7 | 13.2 |
EBIT margin | 9.8% | 5.2% | -12.6% | -21.5% | 7.9% | 25.0% | 14.4% | 42.1% |
Pre-tax income | 30.6 | 11.9 | -19.7 | -30.2 | 7.7 | 17.0 | 6.7 | 13.3 |
Income taxes | -18.8 | 5.7 | 21.1 | -20.7 | 0.1 | 0.1 | 0.1 | 0.1 |
Tax rate | | 47.9% | | 68.4% | 1.8% | 0.5% | 1.1% | 0.9% |
Net income | 49.4 | 6.2 | -40.8 | -9.5 | 3.6 | 10.1 | 3.5 | 13.1 |
Net margin | 15.9% | 2.8% | -26.0% | -6.8% | 3.7% | 14.8% | 7.4% | 41.9% |
|
Diluted EPS | $1.31 | $0.17 | ($1.27) | ($0.39) | $0.21 | $0.58 | $0.19 | |
Shares outstanding (diluted) | 37.6 | 35.9 | 32.2 | 24.7 | 17.3 | 17.3 | 17.9 | |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|